FDA 发布 ANDA 药用固体多晶型 CMC 信息行业指南最终版
ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information
FDA 发布《ANDAs：药用固体多晶型：化学、制造与控制信息》行业指南最终版，文件编号 FDA-2004-D-0182，由 CDER 发布。文件面向原料药存在多晶型情况下的 ANDA 申请人，说明需提交 CMC 信息以支持 ANDA 批准。文件同时说明可随时按 21 CFR 10.115(g)(5) 提交意见。
文件为2007年7月发布的正式指南，说明原料药存在多晶型时 ANDA 需提交的 CMC 信息，并保留随时提交意见的途径。
GUIDANCE DOCUMENT
ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information Guidance for Industry July 2007
Final
- Docket Number:
- FDA-2004-D-0182
- Issued by:
-
Guidance Issuing Office
Center for Drug Evaluation and Research
Chemistry, manufacturing, and controls (CMC) information must be submitted to support the approval of an abbreviated new drug application (ANDA). This guidance is intended to assist applicants with the submission of ANDAs when a drug substance exists in polymorphic forms.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2004-D-0182.
来源：FDA Pharmaceutical Quality Documents · fda.gov